← Library
Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Icatibant

FDA approved · Rx

Bradykinin B2 receptor antagonist

Also known as: Firazyr, Sajazir, icatibanto, HOE140, JE-049, icatibantum, D-Arg(Hyp(3)-Thi(5)-D-Tic(7)-Oic(8))BK, D-Arg(Hyp(3)-Thi(5)-L-Tic(7)-Oic(8))BK

Evidence score
91/ 100
Strong evidence

Strong, human-grade evidence

  • Regulatory standing. FDA-approved prescription medicine
  • Human trials. Backed by controlled human studies
  • Registered human trials. 33 registered studies on ClinicalTrials.gov, most advanced Phase 4
  • 2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Icatibant is a synthetic peptide of ten amino acids, sold under brand names including Firazyr and Sajazir. It blocks the bradykinin B2 receptor, which is thought to reduce the swelling driven by excess bradykinin during attacks of hereditary angioedema.

What the evidence shows

Automatic summaryHuman trials

Icatibant is FDA approved for the treatment of acute attacks of hereditary angioedema in adults, supported by registered human trials up to Phase 4 and a substantial published literature. Evidence for other uses is limited and not established.

Key facts

Molecular formula
C59H89N19O13S
Molecular weight
1304.5 g/mol
FDA approval
Confirmed on openFDA

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

33registered studies
Phase 4most advanced phase
28completed (sample)
0recruiting (sample)

Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor

Phase 3Active Not RecruitingNCT05834777

A Study to Explore Hereditary Angioedema (HAE) Symptoms and Treatment Patterns in Korean People

CompletedNCT06587464

Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)

Phase 3CompletedNCT00500656

The Effect of Ischaemic-Reperfusion in Man - A Bradykinin Dependent Pathway

CompletedNCT00965120

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

775papers referencing Icatibant

Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.

J Clin Invest1997

Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.

Pharmacol Rev1995

Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation.

J Clin Invest1999

Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.

N Engl J Med2010

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.